Fazlul H. Sarkar

Prof. Fazlul H. Sarkar

Wayne State University, USA



1978 PhD Biochemistry, Banaras Hindu, University, India

1974 Graduate: M.Sc., Biochemistry, Aligarh Muslim, University, India (First Class)

1971 Baccalaureate: B.Sc., Physics, Chemistry, Math, Calcutta University, India (Distinction)

Publications (Selected)

  1. S. Ali, A. Ahmad, S. Banerjee, S. Padhye, K. Dominiak, J. M. Schaffert, Z. Wang, P. A. Philip, and F. H. Sarkar. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70 (9):3606-3617, 2010.
  2. A. S. Azmi, P. A. Philip, A. Aboukameel, Z. Wang, S. Banerjee, S. F. Zafar, A. S. Goustin, K. Almhanna, D. Yang, F. H. Sarkar, and R. M. Mohammad. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr.Cancer Drug Targets. 10 (3):319-331, 2010.
  3. S. Ali, S. Banerjee, J. M. Schaffert, B. F. El-Rayes, P. A. Philip, and F. H. Sarkar. Concurrent inhibition of NFkappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem. 110 (1):171-181, 2010.
  4. F. H. Sarkar. (Part I) Recent trends in anti-cancer drug discovery. Mini.Rev.Med Chem. 10 (5):357-358, 2010.
  5. S. Padhye, D. Chavan, S. Pandey, J. Deshpande, K. V. Swamy, and F. H. Sarkar. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini.Rev.Med Chem. 10 (5):372-387, 2010.
  6. A. Ahmad, Z. Wang, R. Ali, M. Y. Maitah, D. Kong, S. Banerjee, S. Padhye, and F. H. Sarkar. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J Cell Biochem. 109 (6):1134-1141, 2010.
  7. Z. Wang, A. Ahmad, Y. Li, S. Banerjee, D. Kong, and F. H. Sarkar. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat.Rev. 36 (2):151-156, 2010.
  8. A. S. Azmi, A. Aboukameel, S. Banerjee, Z. Wang, M. Mohammad, J. Wu, S. Wang, D. Yang, P. A. Philip, F. H. Sarkar, and R. M. Mohammad. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur.J Cancer 46 (6):1122-1131, 2010.
  9. S. Banerjee, M. Choi, A. Aboukameel, Z. Wang, M. Mohammad, J. Chen, D. Yang, F. H. Sarkar, and R. M. Mohammad. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells. Pancreas 39 (3):323-331, 2010.
  10. Z. Wang, Y. Li, and F. H. Sarkar. Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression. Curr.Stem Cell Res.Ther. 5 (1):74-80, 2010.
  11. Z. Wang, Y. Li, S. Banerjee, D. Kong, A. Ahmad, V. Nogueira, N. Hay, and F. H. Sarkar. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem. 109 (4):726-736, 2010.
  12. Y. Li, T. G. Vandenboom, Z. Wang, D. Kong, S. Ali, P. A. Philip, and F. H. Sarkar. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70 (4):1486-1495, 2010.
  13. S. Adsule, S. Banerjee, F. Ahmed, S. Padhye, and F. H. Sarkar. Hybrid anticancer agents: isothiocyanateprogesterone conjugates as chemotherapeutic agents and insights into their cytotoxicities. Bioorg.Med Chem.Lett. 20 (3):1247-1251, 2010.
  14. B. F. El-Rayes, P. A. Philip, F. H. Sarkar, A. F. Shields, A. M. Ferris, K. Hess, A. O. Kaseb, M. M. Javle, G. R. Varadhachary, R. A. Wolff, and J. L. Abbruzzese. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 2010.
  15. I. U. Ahmad, J. D. Forman, F. H. Sarkar, G. G. Hillman, E. Heath, U. Vaishampayan, M. L. Cher, F. Andic, P. J. Rossi, and O. Kucuk. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr.Cancer 62 (7):996-1000, 2010.
  16. S. Banerjee, S. Padhye, A. Azmi, Z. Wang, P. A. Philip, O. Kucuk, F. H. Sarkar, and R. M. Mohammad. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr.Cancer 62 (7):938-946, 2010.
  17. B. Bao, Z. Wang, Y. Li, D. Kong, S. Ali, S. Banerjee, A. Ahmad, and F. H. Sarkar. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim.Biophys.Acta 1815 (2):135-146, 2011.
  18. S. Liao, J. Xia, Z. Chen, S. Zhang, A. Ahmad, L. Miele, F. H. Sarkar, and Z. Wang. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways. J Cell Biochem. 112 (4):1055-1065, 2011.
  19. S. S. Kanwar, Y. Yu, J. Nautiyal, B. B. Patel, S. Padhye, F. H. Sarkar, and A. P. Majumdar. Difluorinated-Curcumin (CDF): A Novel Curcumin Analog is a Potent Inhibitor of Colon Cancer Stem-Like Cells. Pharm.Res. 28 (4):827-838, 2011.
  20. B. Bao, A. S. Prasad, F. W. Beck, G. W. Bao, T. Singh, S. Ali, and F. H. Sarkar. Intracellular free zinc up-regulates IFN-gamma and T-bet essential for Th(1) differentiation in Con-A stimulated HUT-78 cells. Biochem.Biophys.Res.Commun., 2011.
  21. S. Patitungkho, S. Adsule, P. Dandawate, S. Padhye, A. Ahmad, and F. H. Sarkar. Synthesis, characterization and anti-tumor activity of moxifloxacin-Copper complexes against breast cancer cell lines. Bioorg.Med Chem.Lett. 21(6):1802-1806, 2011.
  22. A. Ahmad, A. Aboukameel, D. Kong, Z. Wang, S. Sethi, W. Chen, F. H. Sarkar, and A. Raz. Phosphoglucose Isomerase/Autocrine Motility Factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res., 2011.
  23. A. S. Azmi, F. W. Beck, F. H. Sarkar, and R. M. Mohammad. Network Perspectives on HDM2 InhibitorChemotherapy Combinations. Curr.Pharm.Des, 2011.27
  24. B. Bao, S. Ali, D. Kong, S. H. Sarkar, Z. Wang, S. Banerjee, A. Aboukameel, S. Padhye, P. A. Philip, and F. H. Sarkar. Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer. PLoS.One. 6 (3):e17850, 2011.
  25. A. S. Azmi, Z. Wang, P. A. Philip, R. M. Mohammad, and F. H. Sarkar. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert.Opin.Emerg.Drugs 16 (1):59-70, 2011.
  26. S. Banerjee, D. Kong, A. S. Azmi, Z. Wang, A. Ahmad, S. Sethi, and F. H. Sarkar. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int.J Cancer 128 (5):1240-1250, 2011.
  27. J. Nautiyal, S. Banerjee, S. S. Kanwar, Y. Yu, B. B. Patel, F. H. Sarkar, and A. P. Majumdar. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int.J Cancer 128 (4):951-961, 2011.
  28. V. Singh-Gupta, M. C. Joiner, L. Runyan, C. K. Yunker, F. H. Sarkar, S. Miller, S. M. Gadgeel, A. A. Konski, and G. G. Hillman. Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer. J Thorac.Oncol., 2011.
  29. A. S. Jaiswal, S. Banerjee, R. Aneja, F. H. Sarkar, D. A. Ostrov, and S. Narayan. DNA polymerase beta as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS.One. 6 (2):e16691, 2011.
  30. A. Ahmad, Z. Wang, D. Kong, R. Ali, S. Ali, S. Banerjee, and F. H. Sarkar. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast
  31. Cancer Res.Treat. 126 (1):15-25, 2011.
  32. M. Y. Maitah, S. Ali, A. Ahmad, S. Gadgeel, and F. H. Sarkar. Up-regulation of sonic hedgehog contributes to TGFbeta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS.One. 6 (1):e16068, 2011.
  33. A. S. Azmi, P. A. Philip, F. W. Beck, Z. Wang, S. Banerjee, S. Wang, D. Yang, F. H. Sarkar, and R. M. Mohammad. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene 30 (1):117-126, 2011.
  34. Z. Wang, Y. Li, A. Ahmad, S. Banerjee, A. S. Azmi, D. Kong, C. Wojewoda, L. Miele, and F. H. Sarkar. Downregulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 112 (1):78-88, 2011.
  35. Z. Wang, Y. Li, A. Ahmad, S. Banerjee, A. S. Azmi, D. Kong, and F. H. Sarkar. Pancreatic cancer: understanding and overcoming chemoresistance.Nat.Rev.Gastroenterol.Hepatol. 8 (1):27-33, 2011.
  36. D. Dou, A. Ahmad, H. Yang, and F. H. Sarkar. Tumor cell growth inhibition is correlated with levels of capsaicin present in hot peppers. Nutr.Cancer 63 (2):272-281, 2011.
  37. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26-36. PMC3104092.
  38. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011;29(4):694-9. PMID: 20107864.
  39. Ahmad A, Wang Z, Wojewoda C, Ali R, Kong D, Maitah MY, Banerjee S, Bao B, Padhye S, Sarkar FH. Garcinolinduced apoptosis in prostate and pancreatic cancer cells is mediated by NF- KappaB signaling. Front Biosci (Elite Ed). 2011 Jun 1;3:1483-92. PMID: 21622152.
  40. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wtp53 solid tumors. Oncotarget. 2011 May 16. PMID: 21623005.
  41. Hillman GG, Singh-Gupta V, Al-Bashir AK, Yunker CK, Joiner MC, Sarkar FH, Abrams J, Haacke EM. Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol. 2011;4(2):110-21. PMC3069654.
  42. Kong D, Li Y, Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel). 2011;3(1):716-729. PMC3106306.
  43. Azmi AS, Beck FW, Sarkar FH, Mohammad RM. Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr Pharm Des. 2011;17(6):640-52. PMID: 21391913.